Intomics is taking part in a publicly founded research project within colon cancer. The other project participants are the Technical University of Denmark, Vejle Hospital and the private company Exiqon. The role of Intomics is to analyze and interpret the anonymized NGS data stemming from colon tumors.
CEO of Intomics Thomas Skøt Jensen explains: ”The overall aim of the project is to identify genetic variations of colon tumors enabling better and more precise diagnosis. This again bear promise for optimized and individualized treatment-regiments with improved patient outcomes. Additionally, we expect that the specific project-developed algorithms can be applied more generally to similar challenges within other cancer diseases.”
Recently an article on the project was published. Read more here